SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
With Possible 'Major Public Health Impact,' Malaria Vaccine Advances
Research publication on effectiveness of new vaccine follows announcement by pharmaceutical corporation GlaxoSmithKline that it is applying for first ever approval of anti-malaria vaccine on EU markets.
Jul 30, 2014
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Sarah Lazare
Sarah Lazare is the editor of Workday Magazine and a contributing editor for In These Times. She is a former Staff Writer at Common Dreams. She comes from a background in independent journalism for publications including The Intercept, The Nation, and Tom Dispatch.
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
Sarah Lazare
Sarah Lazare is the editor of Workday Magazine and a contributing editor for In These Times. She is a former Staff Writer at Common Dreams. She comes from a background in independent journalism for publications including The Intercept, The Nation, and Tom Dispatch.
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.